רווח תפעולי לפני ניכוי פחת: Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics (SGMO) corrects genetic malfunctions in the body by transforming DNA into a controllable system. The distribution of EBITDA across periods demonstrates business volatility, while 0.00 describes the current status of the metric. The company is developing ZFP technologies to combat hereditary pathologies by investing in scientific potential. The market is currently awaiting clinical validation and payments from major partners, while operating losses remain priced into the quotes.
Sangamo (SGMO) - פילוחי מדדים ודוחות פיננסיים

This indicator is calculated as the difference between revenue and operating expenses before depreciation and taxes, reflecting the business's net ability to generate cash flow. An analysis of quarterly EBITDA allows for an assessment of the capitalization efficiency of the unique zinc finger platform of Sangamo Therapeutics (SGMO) and the resilience of its partnerships with healthcare leaders.